Exact Sciences Corporation

EXAS

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

OrbiMed Advisors Perceptive Advisors Rock Springs Capital

Position Trend

Feb 13, 2026

$25.9M

1 fund

Feb 17, 2026

$218.8M

3 funds

+745% total institutional value over 2 quarters

Catalysts

Phase 2Dec 15, 2026Modified FOLFIRINOXLocally Advanced Pancreatic Adenocarcinoma

Position Details

OrbiMed AdvisorsNEWFeb 17, 2026

Shares: 351,716Value: $35.7M

**Signal Note: OrbiMed Initiates $35.7M Position in Exact Sciences (EXAS)** OrbiMed's new $35.7M stake signals conviction in EXAS's oncology screening portfolio, particularly Cologuard (colorectal cancer screening) and its higher-margin follow-on tests. The position timing may reflect confidence in upcoming clinical validation data, reimbursement expansion, or market share gains as Cologuard penetration increases in the ~80M eligible U.S. screening population.

Perceptive AdvisorsNEWFeb 17, 2026

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

DYN4 funds ISRG4 funds BSX4 funds RVMD4 funds SION4 funds NBIX3 funds OLMA3 funds IRON

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Perceptive Advisors Initiates $121.9M EXAS Position Edelman's entry into Exact Sciences signals confidence in the company's non-invasive cancer screening platform, particularly Cologuard (colorectal cancer) and Galleri (multi-cancer detection), as adoption accelerates post-Medicare coverage expansion. The $121.9M position (1.2M shares) represents meaningful conviction from an investor with a strong track record backing clinical-stage assets, suggesting confidence in either Galleri's commercialization trajectory or pipeline catalysts (ongoing clinical data readouts for additional cancer types).